Look under the
 microscope at iVS-1
Look under the microscope at iVS-1
The world’s most researched strain of B. adolescentis should be included in today’s biotic-based supplements as a foundational strain supporting gastrointestinal health, wellbeing and longevity.
 Contact
Introducing iVS-1®
B. adolescentis
Most species of Bifidobacterium decline as we get older. However, research has shown that B. adolescentis, in particular, remains abundant in healthy children and adults throughout life, and is considered vital to a balanced gut microbiota, potentially possessing anti-aging properties.1
Despite the significant presence of B. adolescentis in the human microbiome throughout life, most of today’s dietary supplements are missing this key microbe for lifelong health.
2010 1 / 5
The IVS Platform Emerges
Researchers working at the University of Nebraska-Lincoln (UNL) develop a next-generation screening system, The IVS Platform™, to study the growth and behavior of probiotics within the human gut microbiome by selectively feeding a range of precision prebiotic fibers.
Leser T, Baker A. Bi dobacterium adolescentis - a bene cial microbe. Benef Microbes. 2023 Nov 27;14(6):525-551. doi: 10.1163/18762891-20230030. PMID: 38350464.

Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14. PMID: 21059476.

Davis LM, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly speci c bi dogenic response in humans. PLoS One. 2011;6(9):e25200. doi: 10.1371/journal.pone.0025200. Epub 2011 Sep 26. PMID: 21966454; PMCID: PMC3180383.

Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE, Rasineni K, Ramer-Tait AE, Harris EN, Hutkins RW, Walter J. In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol. 2015 Apr;81(7):2455-65. doi: 10.1128/AEM.03903-14. Epub 2015 Jan 23. PMID: 25616794; PMCID: PMC4357922.

Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bi dobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. PMID: 29954454; PMCID: PMC6022452.

2015 2 / 5
The Discovery of iVS-1
The IVS Platform is used during a clinical investigation. When college-aged subjects consume the prebiotic GOS, researchers at UNL found that Bifidobacteria levels markedly increased, particularly in one elite athlete who showed a significant upsurge of a unique strain of Bifidobacterium adolescentis. The strain discovered in this groundbreaking research is designated iVS-1®.
Leser T, Baker A. Bi dobacterium adolescentis - a bene cial microbe. Benef Microbes. 2023 Nov 27;14(6):525-551. doi: 10.1163/18762891-20230030. PMID: 38350464.

Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14. PMID: 21059476.

Davis LM, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly speci c bi dogenic response in humans. PLoS One. 2011;6(9):e25200. doi: 10.1371/journal.pone.0025200. Epub 2011 Sep 26. PMID: 21966454; PMCID: PMC3180383.

Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE, Rasineni K, Ramer-Tait AE, Harris EN, Hutkins RW, Walter J. In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol. 2015 Apr;81(7):2455-65. doi: 10.1128/AEM.03903-14. Epub 2015 Jan 23. PMID: 25616794; PMCID: PMC4357922.

Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bi dobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. PMID: 29954454; PMCID: PMC6022452.

2018 3 / 5
Synbiotic Health is Formed
Synbiotic Health is founded in 2018 to bring the benefits of iVS-1, as well as other novel microbes developed using the IVS Platform, to leading global dietary supplement brands looking to fortify their formulations with targeted, ecologically-sourced biotics.
Leser T, Baker A. Bi dobacterium adolescentis - a bene cial microbe. Benef Microbes. 2023 Nov 27;14(6):525-551. doi: 10.1163/18762891-20230030. PMID: 38350464.

Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14. PMID: 21059476.

Davis LM, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly speci c bi dogenic response in humans. PLoS One. 2011;6(9):e25200. doi: 10.1371/journal.pone.0025200. Epub 2011 Sep 26. PMID: 21966454; PMCID: PMC3180383.

Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE, Rasineni K, Ramer-Tait AE, Harris EN, Hutkins RW, Walter J. In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol. 2015 Apr;81(7):2455-65. doi: 10.1128/AEM.03903-14. Epub 2015 Jan 23. PMID: 25616794; PMCID: PMC4357922.

Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bi dobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. PMID: 29954454; PMCID: PMC6022452.

2022 4 / 5
Madison Research Lab Opens
To further strengthen their commercial offerings, Synbiotic Health inaugurates a research lab in Madison, Wisconsin, focused on the development, scale-up and optimization of probiotic strains isolated using the IVS Platform, as well other proprietary screening systems, at Synbiotic Health’s discovery lab at University of Nebraska-Lincoln.
Leser T, Baker A. Bi dobacterium adolescentis - a bene cial microbe. Benef Microbes. 2023 Nov 27;14(6):525-551. doi: 10.1163/18762891-20230030. PMID: 38350464.

Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14. PMID: 21059476.

Davis LM, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly speci c bi dogenic response in humans. PLoS One. 2011;6(9):e25200. doi: 10.1371/journal.pone.0025200. Epub 2011 Sep 26. PMID: 21966454; PMCID: PMC3180383.

Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE, Rasineni K, Ramer-Tait AE, Harris EN, Hutkins RW, Walter J. In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol. 2015 Apr;81(7):2455-65. doi: 10.1128/AEM.03903-14. Epub 2015 Jan 23. PMID: 25616794; PMCID: PMC4357922.

Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bi dobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. PMID: 29954454; PMCID: PMC6022452.

2024 5 / 5
iVS-1® Commercial Launch
Following several years of concerted focus on fermentation techniques, scale-up, production enhancement and yield improvement, iVS-1 is made available for global commercial sale. Synbiotic Health distinguishes itself by offering the most optimized, well-characterized, and commercially-viable B. adolescentis strain in the world.
Leser T, Baker A. Bi dobacterium adolescentis - a bene cial microbe. Benef Microbes. 2023 Nov 27;14(6):525-551. doi: 10.1163/18762891-20230030. PMID: 38350464.

Davis LM, Martínez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14. PMID: 21059476.

Davis LM, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly speci c bi dogenic response in humans. PLoS One. 2011;6(9):e25200. doi: 10.1371/journal.pone.0025200. Epub 2011 Sep 26. PMID: 21966454; PMCID: PMC3180383.

Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE, Rasineni K, Ramer-Tait AE, Harris EN, Hutkins RW, Walter J. In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol. 2015 Apr;81(7):2455-65. doi: 10.1128/AEM.03903-14. Epub 2015 Jan 23. PMID: 25616794; PMCID: PMC4357922.

Krumbeck JA, Rasmussen HE, Hutkins RW, Clarke J, Shawron K, Keshavarzian A, Walter J. Probiotic Bi dobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome. 2018 Jun 28;6(1):121. doi: 10.1186/s40168-018-0494-4. PMID: 29954454; PMCID: PMC6022452.

References
University of Nebraska

The University of Nebraska-Lincoln is marking more than 100 years of research into probiotics and the discovery of beneficial microbes. One significant achievement was the development of Lactobacillus acidophilus DDS®-1, which continues to be one of the most popular probiotic strains in the world. By 2018, when the Nebraska Food for Health Center was established, over 50 faculty, staff, and students were actively researching gut health. That same year, a new 5,000 square-foot facility was built, including a gut biology lab, a clinical research center, an analytical lab, and other specialized research spaces.

DDS®-1 is a registered trademark of Novonesis A/S.
Synbiotic Health

Synbiotic Health was founded in 2018 by four leading microbiome researchers from the University of Nebraska-Lincoln: Dr. Bob Hutkins, Dr. Andy Benson, Dr. Jens Walter, and Dr. Tom Burkey, who together have over 100 years of experience in the field. Tim Brummels joined the company as CEO in 2019. Their signature probiotic strain, iVS-1®, was discovered in the university’s research labs and is exclusively licensed to Synbiotic Health. The company’s mission is to develop vital probiotic microbes aimed at improving quality of life, supporting healthy aging, and enhancing overall human health

Strain Collection

Synbiotic Health, in close coordination with the University of Nebraska-Lincoln, has amassed a large collection of human-origin strains, as well a unique portfolio of canine-derived strains.

Human strains
850 isolates identified by sequencing
> 400 Lactobacillus and Bifidobacterium strains
30 genome sequenced and characterized strains
20 strains with pre-clinical properties
9 strains in pre-production & scale up
4 strains selected for human clinical trials

Canine strains
535 isolates identified by sequencing
> 350 Lactobacillus and Bifidobacterium strains
20 whole genome sequenced and characterized strains
8 AAFCO approved strains with pre-clinical properties
5 strains in pre-production & scale up